Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up

Bhavana Pothuri, Allison L. Brodsky, Joseph A. Sparano, Stephanie V. Blank, Mimi Kim, Dawn L. Hershman, Amy Tiersten, Brian F. Kiesel, Jan H. Beumer, Leonard Liebes, Franco Muggia

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds